[CAS NO. 1384426-12-3]  NT157

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1384426-12-3]

Store
Catalog
SLK-S8228
Brand
Selleck
CAS
1384426-12-3

DESCRIPTION [1384426-12-3]

Overview

MDL-
Molecular Weight412.26
Molecular FormulaC16H14BrNO5S
SMILESC1=C(C=C(C(=C1O)O)O)CNC(=S)C=CC2=CC(=C(C(=C2)Br)O)O

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM2.4257 mL12.1283 mL24.2565 mL
5 mM0.4851 mL2.4257 mL4.8513 mL
10 mM0.2426 mL1.2128 mL2.4257 mL
50 mM0.0485 mL0.2426 mL0.4851 mL

Description

NT157, a selective inhibitor of , has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival.

Targets

IRS1/2 [2]

In vitro

NT157 treatment resulted in dose-dependent inhibition of IGF1R activation, suppression of IRS protein expression, inhibition of IGF1-induced AKT activation, but increased ERK activation in NT157-treated cells in vitro. These effects were correlated with decreased proliferation and increasing apoptosis of LNCaP cells and increasing G2-M arrest in PC3 cells. NT157 can mediate suppression of IGF1R-mediated survival signaling through the established mechanism for negative feedback of IGF1R signaling: targeting IRS1/2 for serine phosphorylation and subsequent degradation. NT157 displayed little to no effect on the survival of normal melanocytes and fibroblasts.

In vivo

NT157 suppressed androgen-responsive growth, delayed CRPC progression of LNCaP xenografts, and suppressed PC3 tumor growth alone and in combination with docetaxel. Melanoma tumor growth and metastasis is efficiently inhibited by NT157.